- Home
- APPS vs PALI Comparison
APPS vs PALI Comparison
Compare APPS & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APPS | PALI |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 346.5M | 348.7M |
| IPO Year | 2012 | 2019 |
Fundamental Metrics
Financial Performance| Metric | APPS | PALI |
|---|---|---|
| Price | $3.89 | $1.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $6.25 | ★ $11.29 |
| AVG Volume (30 Days) | 1.9M | ★ 4.2M |
| Earning Date | 06-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 78.61 | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,569,000.00 | $260,000.00 |
| Revenue This Year | $15.60 | N/A |
| Revenue Next Year | $11.34 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 38.55 | ★ 1500.39 |
| 52 Week Low | $2.74 | $0.55 |
| 52 Week High | $8.28 | $2.86 |
Technical Indicators
Market Signals| Indicator | APPS | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 60.38 | 47.00 |
| Support Level | $3.78 | $1.57 |
| Resistance Level | $4.07 | $2.05 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 76.13 | 7.85 |
Price Performance
Historical ComparisonAbout APPS Digital Turbine Inc.
Digital Turbine Inc is an independent mobile growth platform. It offers end-to-end products and solutions to all participants in the mobile application ecosystem, enabling brand discovery and advertising, user acquisition and engagement, and operational efficiency for advertisers. Its operating segments are On Device Solutions and App Growth Platform.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.